NCT04557267 is a Phase 2 clinical trial of low-dose in Obesity, sponsored by Indonesia University.

Who is sponsoring NCT04557267?

NCT04557267 is sponsored by Indonesia University.

What drugs are being tested in NCT04557267?

Interventions in NCT04557267: low-dose, Middle-dose, Higher-dose, Placebo.

Is NCT04557267 still recruiting?

NCT04557267 is currently completed. Last updated 3 June 2021.

Last reviewed 2021-06-03 · How we verify

NCT04557267

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose-ranging Study of SKF7™ for Obesity

Completed Phase 2 Last updated 3 June 2021

What this trial tests

Phase 2 trial testing low-dose in Obesity in 160 participants. Completed in 22 May 2021.

Timeline

30 September 2020

Primary endpoint
20 May 2021

22 May 2021

Quick facts

Lead sponsor	Indonesia University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	160
Start date	30 September 2020
Primary completion	20 May 2021
Estimated completion	22 May 2021
Sites	3 locations across Indonesia

Drugs / interventions tested

low-dose
Middle-dose
Higher-dose — full drug profile →
Placebo

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Indonesia University

Who can join

Adults 18 to 50, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study has been designed as a randomized, double blinded, multi-centric, placebo controlled, and phase II dose-ranging study. The herbal drug contains bioactive ingredients from Labisia pumila plant and it is an aqueous ethanolic standardized extract (SKF7™).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Signaling pathways in obesity: mechanisms and therapeutic interventions.
Wen X, Zhang B, Wu B, Xiao H, et al · · 2022 · cited 245× · PMID 36031641 · DOI 10.1038/s41392-022-01149-x
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.
Nicze M, Dec A, Borówka M, Krzyżak D, et al · · 2024 · cited 9× · PMID 39125772 · DOI 10.3390/ijms25158202

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Indonesia University trials

Trials by the same sponsor.

NCT07137130 — Secretome TGF Beta 3 · NA · not yet recruiting
NCT07420335 — Preoperative Shoulder Exercises and Postoperative Inflammation, Pain, and Function After Modified Radical Mastectomy · NA · not yet recruiting
NCT07278284 — The Effectiveness of Press Needle Acupuncture on Preoperative Anxiety in Tympanoplasty and Mastoidectomy · NA · recruiting
NCT07337187 — Effect of Thread-Embedding Acupuncture at EX-B2 on Pain and Quality of Life in Chronic Low Back Pain · NA · not yet recruiting
NCT07242001 — Laser Acupuncture for Otitis Media With Effusion in Children · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04557267 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indonesia University
Last refreshed: 3 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04557267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing